Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
がんを処置するための方法および組成物
Document Type and Number:
Japanese Patent JP7189160
Kind Code:
B2
Abstract:
Embodiments are directed to: (i) neutrophil secreted factors that have the capacity to kill a broad range of cancer cells without affecting the viability of non-cancer cells. Two neutrophil killing factors have been identified by the inventors: (1) eosinophil cationic protein (ECP) and (2) neutrophil elastase (ELANE); or (ii) therapeutic compositions that include CD95 degrading polypeptide components and methods of treating cancer with the same.

Inventors:
becker rev
Cui Chan
Application Number:
JP2019569454A
Publication Date:
December 13, 2022
Filing Date:
June 15, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
THE UNIVERSITY OF CHICAGO
International Classes:
A61K38/17; A61K38/48; A61K45/00; A61K47/51; A61P35/00; A61P43/00
Domestic Patent References:
JP2004123679A
JP2006500944A
Foreign References:
WO2016125330A1
Other References:
DE Lima, P. O. et al.,Effect of eosinophil cationic protein on human oral squamous carcinoma cell viability,Molecular and Clinical Oncology,2015年,Vol.3, No.2,p.353-356,doi:10.3892/mco.2014.477
Ho, A. S. et al.,Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers,Oncotarget,2014年,Vol.5, No.2,p.473-480,doi:10.18632/oncotarget.1631
Hadji, A. et al.,Death induced by CD95 or CD95 ligand elimination,Cell Reports,2014年,Vol.7, No.1,p.208-222,doi:10.1016/j.celrep.2014.02.035
Attorney, Agent or Firm:
Shimizu Hatsushi
Masao Haruna
Hirotaka Yamaguchi
Shun Jinbe
Ryuichi Inoue
Toshimitsu Sato
Koichi Niimi
Tomohiko Kobayashi
Hideki Kodera
Masato Ozeki
Kazuya Kawamoto